Setor K Kunutsor1,2, Jari A Laukkanen3,4,5. 1. National Institute for Health Research Bristol Biomedical Research Centre, University Hospitals Bristol and Weston NHS Foundation Trust and the University of Bristol, Bristol, United Kingdom. 2. Translational Health Sciences, Bristol Medical School, University of Bristol, Learning and Research Building (Level 1), Southmead Hospital, Bristol, United Kingdom. 3. Institute of Clinical Medicine, Department of Medicine, University of Eastern Finland, Kuopio, Finland. 4. Department of Medicine, Central Finland Health Care District, Jyväskylä, Finland. 5. Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland.
Abstract
BACKGROUND AND OBJECTIVE: Serum magnesium, an essential trace element involved in processes that regulate cardiovascular function, has been linked to the risk of atherosclerotic cardiovascular disease. However, the potential association between serum magnesium and venous thromboembolism (VTE) has not been previously investigated. We aimed to assess the prospective association of serum magnesium with the risk of VTE. METHODS: Serum magnesium was measured using atomic absorption spectrometry in 2,361 men aged 42-61 years with no history of VTE at baseline in the Kuopio Ischemic Heart Disease prospective cohort. Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for VTE. RESULTS: A total of 159 incident VTE events were recorded during a median follow-up of 27.1 years. The risk of VTE per 1 SD increase in serum magnesium in the age-adjusted analysis was (HR 1.30; 95% CI 0.46-3.69). The association remained consistent in analyses adjusted for systolic blood pressure, body mass index, total cholesterol, triglycerides, smoking status, a history of type 2 diabetes, a history of coronary heart disease, medication for dyslipidemia, alcohol consumption, physical activity, socioeconomic status, serum active calcium, high-sensitivity C-reactive protein, and a history of cancer (HR 1.38; 95% CI 0.48-3.96). Comparing the extreme tertiles of serum magnesium, the corresponding adjusted HRs were 1.17 (95% CI 0.81-1.70) and 1.17 (95% CI 0.81-1.70), respectively. CONCLUSION: In a middle-aged Caucasian male population, serum-circulating magnesium was not associated with a future risk of VTE. Further studies in women, other age groups, and other populations are required to generalize these findings.
BACKGROUND AND OBJECTIVE: Serum magnesium, an essential trace element involved in processes that regulate cardiovascular function, has been linked to the risk of atherosclerotic cardiovascular disease. However, the potential association between serum magnesium and venous thromboembolism (VTE) has not been previously investigated. We aimed to assess the prospective association of serum magnesium with the risk of VTE. METHODS: Serum magnesium was measured using atomic absorption spectrometry in 2,361 men aged 42-61 years with no history of VTE at baseline in the Kuopio Ischemic Heart Disease prospective cohort. Cox regression models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for VTE. RESULTS: A total of 159 incident VTE events were recorded during a median follow-up of 27.1 years. The risk of VTE per 1 SD increase in serum magnesium in the age-adjusted analysis was (HR 1.30; 95% CI 0.46-3.69). The association remained consistent in analyses adjusted for systolic blood pressure, body mass index, total cholesterol, triglycerides, smoking status, a history of type 2 diabetes, a history of coronary heart disease, medication for dyslipidemia, alcohol consumption, physical activity, socioeconomic status, serum active calcium, high-sensitivity C-reactive protein, and a history of cancer (HR 1.38; 95% CI 0.48-3.96). Comparing the extreme tertiles of serum magnesium, the corresponding adjusted HRs were 1.17 (95% CI 0.81-1.70) and 1.17 (95% CI 0.81-1.70), respectively. CONCLUSION: In a middle-aged Caucasian male population, serum-circulating magnesium was not associated with a future risk of VTE. Further studies in women, other age groups, and other populations are required to generalize these findings.
Authors: Simon Barquera; Andrea Pedroza-Tobías; Catalina Medina; Lucía Hernández-Barrera; Kirsten Bibbins-Domingo; Rafael Lozano; Andrew E Moran Journal: Arch Med Res Date: 2015-06-29 Impact factor: 2.235
Authors: S MacMahon; R Peto; J Cutler; R Collins; P Sorlie; J Neaton; R Abbott; J Godwin; A Dyer; J Stamler Journal: Lancet Date: 1990-03-31 Impact factor: 79.321
Authors: Setor K Kunutsor; Samuel Seidu; Ashley W Blom; Kamlesh Khunti; Jari A Laukkanen Journal: Eur J Epidemiol Date: 2017-07-17 Impact factor: 8.082
Authors: John Gregson; Stephen Kaptoge; Thomas Bolton; Lisa Pennells; Peter Willeit; Stephen Burgess; Steven Bell; Michael Sweeting; Eric B Rimm; Christopher Kabrhel; Bengt Zöller; Gerd Assmann; Vilmundur Gudnason; Aaron R Folsom; Volker Arndt; Astrid Fletcher; Paul E Norman; Børge G Nordestgaard; Akihiko Kitamura; Bakhtawar K Mahmoodi; Peter H Whincup; Matthew Knuiman; Veikko Salomaa; Christa Meisinger; Wolfgang Koenig; Maryam Kavousi; Henry Völzke; Jackie A Cooper; Toshiharu Ninomiya; Edoardo Casiglia; Beatriz Rodriguez; Yoav Ben-Shlomo; Jean-Pierre Després; Leon Simons; Elizabeth Barrett-Connor; Cecilia Björkelund; Marlene Notdurfter; Daan Kromhout; Jackie Price; Susan E Sutherland; Johan Sundström; Jussi Kauhanen; John Gallacher; Joline W J Beulens; Rachel Dankner; Cyrus Cooper; Simona Giampaoli; Jason F Deen; Agustín Gómez de la Cámara; Lewis H Kuller; Annika Rosengren; Peter J Svensson; Dorothea Nagel; Carlos J Crespo; Hermann Brenner; Juan R Albertorio-Diaz; Robert Atkins; Eric J Brunner; Martin Shipley; Inger Njølstad; Deborah A Lawlor; Yvonne T van der Schouw; Randi Marie Selmer; Maurizio Trevisan; W M Monique Verschuren; Philip Greenland; Sylvia Wassertheil-Smoller; Gordon D O Lowe; Angela M Wood; Adam S Butterworth; Simon G Thompson; John Danesh; Emanuele Di Angelantonio; Tom Meade Journal: JAMA Cardiol Date: 2019-02-01 Impact factor: 14.676